The "Cysts" Were Never the Problem — What the PCOS Rename Really Means
For years, women with PCOS have been handed a diagnosis that pointed at the wrong thing.
In May 2025, that changed — at least officially. After an 11-year global consensus process involving more than 22,000 patients and clinicians, The Lancet announced that PCOS has been renamed polyendocrine metabolic ovarian syndrome, or PMOS. A simultaneous paper in JAMA Internal Medicine confirmed what the new name implies: the condition was never really about ovarian cysts to begin with.
The Cysts That Weren't Cysts
The "polycystic" in PCOS was always a misnomer. What ultrasound imaging has been picking up for decades isn't a collection of pathological cysts. It was actually an accumulation of small, immature follicles. Specifically, antral follicles between 2 and 9 millimeters.
In any woman's normal menstrual cycle, the body begins with a pool of these immature follicles. As the cycle progresses, one dominant follicle matures and is released at ovulation. However, in women with PMOS, this process gets disrupted before it can complete. The follicles stall and accumulate. And that is what we see on an ultrasound, and what gets labeled "cysts."
But they aren't. True ovarian cysts, such as endometriomas, dermoid cysts, hemorrhagic cysts, are structurally distinct, typically larger, and can cause pain, torsion, or rupture. The follicles seen in PMOS meet none of those criteria.
The JAMA paper concluded that the concern over pathological ovarian cysts in PCOS is, in the researchers' own words, "unfounded."
Where the Problem Actually Lives
The rename reflects a more accurate picture of what's happening in the body.
PMOS is driven by disruptions in insulin, androgens, and neuroendocrine signalling. Insulin resistance is present in roughly 85% of women with this pattern and it causes elevated insulin levels, which in turn stimulate the ovaries to produce excess androgens. Those androgens interfere with normal follicular development, preventing ovulation and leading to the cycle irregularities and other symptoms the condition is known for.
Elevated AMH, now formally included as a diagnostic criterion, is another downstream consequence of this same process.
The metabolic dimension extends well beyond cycle irregularity. Unaddressed insulin resistance going into pregnancy raises the risk of gestational diabetes, preeclampsia, and other serious complications. For women trying to conceive, this is critical context.
Diagnosis Is Changing — But Will Treatment?
The updated guidelines reflect meaningful shifts. Clinical signs of hyperandrogenism alongside irregular cycles may now be sufficient for diagnosis without requiring bloodwork. Ultrasound is being de-emphasized. AMH has been added as a formal marker.
These changes make the diagnostic process more accessible and more accurate.
The harder question is whether treatment will follow. The conventional approach to this condition has long relied on hormonal contraceptives to "regulate" cycles and metformin to manage blood sugar. Neither addresses the root cause. The birth control pill doesn't resolve insulin resistance, reduce inflammation, or correct androgen excess. Instead it suppresses the cycle, creates a predictable withdrawal bleed, and leaves the underlying dysfunction untouched.
A truly metabolic framing of this condition demands a metabolic response — one that addresses blood sugar regulation, systemic inflammation, and the neuroendocrine environment that shapes ovarian function.
What Root-Cause Care Looks Like
When women with PMOS receive care that addresses the underlying endocrine and metabolic drivers, the results are often striking. Their cycles regulate, hormones normalize, and ovulation returns. The immature follicles that were stuck in a holding pattern begin to progress as they should. Women who were told IVF was their only option have gone on to conceive naturally.
The body, given the right conditions, is capable of remarkable resilience. This is true healing. It's what happens when you stop silencing symptoms and start listening to what they're saying.
The rename matters. But what matters more is what does the treatment look like.
Sources:
Teede HJ, Mahnaz Bahri Khomami, Morman R, et al. Polyendocrine metabolic ovarian syndrome, the new name for polycystic ovary syndrome: a multistep global consensus process.The Lancet. 2026;0(0). doi:https://doi.org/10.1016/S0140-6736(26)00717-8
Piltonen TT, Kuusiniemi E, Teede H. Ovarian Cysts in Polycystic Ovary Syndrome.JAMA Internal Medicine. Published online May 11, 2026. doi:https://doi.org/10.1001/jamainternmed.2026.1370
